Council Members in this Study Group: 767
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Leading institutions connect with members of this Study Group through GLG
Hany SalamaVice President, Commercial Operations
NEOSTRATA COMPANY, INC. ![]()
Hany Salama, ME, MBA, CPM, is the Vice President, Commercial Operations at The NeoStrata Company. He has global responsibilities for commercial planning, supply chain, and manufacturing operations for all clinical and marketed products. Mr. Salama is also responsible for all new commercial productlaunches...
System Director of Purchasing
HALLMARK HEALTH SYSTEM, INC. ![]()
Louis Rocco is the System Director of Purchasing at Hallmark Health System, in Massachusetts. He has over 25 years of experience in purchasing and has negotiation, analytical, reporting and communication skills in inventory, distribution, purchasing, mailroom, reimbursement and accounts payable background....
Adam Fein, PhDFounder & President
PEMBROKE CONSULTING INC ![]()
Adam Fein, PhD, is the Founder and President of Pembroke Consulting, Inc., a Philadelphia-based management advisory and business research firm. Dr. Fein is one of the country’s foremost experts on pharmacy economics and the pharmaceutical supply chain. He provides strategic advisory services to a diverse...
Stephen BentPartner
FOLEY & LARDNER LLP ![]()
Stephen A. Bent is Partner and former co-leader of the Life Sciences Industry Team at Foley & Lardner in Washington, DC. He is also a member of the Biotechnology & Pharmaceutical Practice Group and the Health Care and Nanotechnology Industry Teams. Mr. Bent specializes on the legal issues associated...
Principal
Law Offices of Michael D. McNeely ![]()
Michael McNeely is in private practice in Washington, DC, where he provides antitrust counseling and representation. Mr. McNeely consults on the antitrust and antitrust agency aspects of mergers, generic drug approvals, telecommunications, patents, standard setting, and other topics. He also represents...
Eric Gruff, PhD MBAPrincipal
E4 Consulting ![]()
Eric Gruff, PhD, MBA, BS, is Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 17 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...
Obstetrician and Gynecologist
ALAN B PATTERSON MD, PA ![]()
Alan Patterson, MD, is an Obstetrician and Gynecologist at Alan B Patterson MD, a private practice in Florida, since May 1991. Dr. Patterson was on the teaching staff at Methodist Hospital, Indianapolis, where he wrote many protocols for the residency program. In the past few years, Dr. Patterson has...
Adjunct Professor
THE UNIVERSITY OF QUEENSLAND ![]()
Evan Siegel, M Phil, Ph D, is the President and Chief Executive Officer of Ground Zero Pharmaceuticals, a regulatory affairs and product development consulting firm in California, since June 1999. Dr. Siegel is also an Adjunct Professor at the University of Queensland, since November 2006. He provides...
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
A triple combination for H1N1: good in principle
October 30, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com
The principle behind Adamas’s triple combination development for influenza is a good one. There is clearly a need for improved treatments, as the latest wave of swine flu is now showing. Oseltamivir (Tamiflu) and ribavirin are reasonable drugs to select but the third component, amantadine, may prove...
Express Scripts feeling Growing Pains
October 29, 2009
Express Scripts to Close NextRx Deal in 4Q | quicktake.morningstar.com
On 11/04/09 TriCare, the health insurance plan for the US Military and its families are being moved to a new pharmacy benefit administered by Express Scripts. Despite assurances of transparency and no change in pharmacies, thousands of beneficiaries are being directed by Express Scripts to a single...
Turn around signs seen in healthcare !!! Dr. Reddy's & Ranbaxy beat the trend!!!
October 27, 2009
UPDATE 1-New generics help India Dr Reddy's beat Q2 f'cast | in.reuters.com
After 4 - 5 quaters of negative growth, cost cuts, product rationalization etc... we have some good news from bell weather stocks of Indian pharma market.Dr. Reddy's & Ranbaxy both are reporting profits after of year of dismal performance.This is also a sign of overall market changing its down ward...
Particle Beam Radiation Therapy (PBRT) life saving technology but who will pay?
October 22, 2009
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
PBRT is an exciting technology that has emerged as a life saver for children and many adults with head/neck , eye and other difficult to treat cancers. Proton Centers require massive investments from $100-250 million. Payor groups from Medicare to commercial plans are faced with whether to pay forthis...
GSK's new venture into Duchenne's makes sense
October 14, 2009
John Ansell, MBA, Director, John Ansell Consultancy
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy | www.pipelinereview.com
GSK's latest deal on Duchenne's muscular dystrophy with the Dutch company Prosena is a further indication of the former's interest in diversifying out of the more obvious, major areas of medicine.This can make sense: such "esoteric" indications areas are less well understood, there is less competition...
| Study Group Name | No. Members |
|---|---|
| Pharmacists (US) | 2079 |
| Experts on Generic Pharmaceuticals: Pharmacists | 107 |
| Economic Experts on Managed Care | 716 |
| Formulary Design Experts | 252 |
| Managed Care Experts | 670 |
| Medicare Experts | 495 |
| Generic Pharmaceuticals Regulation Experts: Healthcare Consultants | 45 |
Leading Experts in Generic Drug Economic Experts Study Group have not participated in any upcoming seminars.
View All GLG Live Meetings in Healthcare
Leading Experts in Generic Drug Economic Experts have not participated in any GLG webcasts.